

Strainsforpains Inc. Announces Substantial Increase In Revenues for 2023

NEW YORK, April 15, 2024 (E-Buy Homes, Inc. DBA/Strainsforpains, Inc.) (OTC Markets: EBYH)

Strainsforpains, Inc. is pleased to announce that it has released its annual report, showing increased sales of 1000% from \$7400 in 2022 to \$84,000 in 2023. The company has announced that its first quarter 2024 has seen a \$130,000 order for its CBD products as well.

Mr. Shainberg, Strainsforpains president stated that “We anticipate 2024 to be a milestone year for us, not just with major increases in revenues, but also joint ventures in developments of new products, licensing agreements, upgrade to our pain management app utilizing the latest in artificial intelligence, and the finalization of our seven acre Pennsylvania facility renovations for manufacturing and distribution of CBD products”.

The company is working with scientists and doctors well known in their fields, in areas of water solubility of CBD, as well as new anti-inflammatory additives to our CBD products. We have entered into a licensing deal with GenBio, primarily a US-based biotech research Company, and its mission is to develop the next generation of anti-inflammatory drugs.

Strainsforpains is also progressing towards its change of symbol on the OTC Markets, with its upcoming audited financials within 2024.

Overview of Strainsforpains, Inc.: Please visit our website at <http://www.strainsforpains.com/>. Strainsforpains, Inc. is an innovative healthcare data technology Company located in New York, N.Y. The Company’s objectives are to provide doctors, nurses, dispensaries, and patients access to an APP that will allow for an advanced determination of comparison of strains or brands of cannabis combinations with major illnesses, in a user-friendly manner. The company is developing beyond its initial CBD product for muscle pain, with a line of branded products addressing specific types of pain and physiological conditions. The company owns a 7 acre facility in Pennsylvania that will be used for CBD product production. Mr. Shainberg is a member of the prestigious International Cannabinoid Research Society, <https://icrs.co/>.

Safe Harbor Statement: Statements in this press release that are not historical fact may be deemed forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.

Although Strainsforpains, Inc. believes the expectations reflected in any forward-looking statements are based on reasonable assumptions, Strainsforpains, Inc. is unable to give any assurance that its expectations will be attained. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Strainsforpains, Inc.'s ability to control, and those actual results may differ materially from those projected in the forward-looking statements as a result of various factors. More information about the potential factors that could affect the business and financial results is and will be included in Strainsforpains, Inc. filings with the Securities and Exchange Commission and OTC Markets.

For further info and Media Contact:

simon@strainsforpains.com 347-218-0844 244 Fifth Avenue Suite S242, New York, N.Y. 10001

Sean Goodwin: 10Kstrains@gmail.com

<https://www.facebook.com/profile.php?id=100071016855607>

<https://twitter.com/strainsforpains>

https://www.instagram.com/strains_for_pains/

<https://www.linkedin.com/company/strainsforpains/?viewAsMember=true>

<https://audioboom.com/posts/8466160-strainsforpains-inc-discusses-inspiration-app-technology-and-cbd-market-entrance-with-the-stoc>

<https://www.youtube.com/watch?v=E-lftNrcFLk>